<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816556</url>
  </required_header>
  <id_info>
    <org_study_id>07-008730</org_study_id>
    <secondary_id>UL1TR000135</secondary_id>
    <nct_id>NCT00816556</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maire Mac Bride</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrophic vaginitis is a common problem that occurs in up to 40% of postmenopausal women. The
      main symptoms are dryness, itching and burning in and around the vagina. These symptoms in
      turn can cause pain with intercourse. Other symptoms can include urinary frequency and
      urinary urgency. These symptoms are caused by the decreasing levels of estrogens in
      postmenopausal women.

      The current treatment options include hormone replacement therapy by mouth and patch and
      vaginal creams, tablets and rings. The current guideline recommend using hormone therapy at
      the lowest dose for the shortest time. We are trying to find the lowest effective dose of
      estrogen cream that helps with symptoms without causing an increase in estrogens in the blood
      stream.

      We want to compare two estrogen creams, estradiol and estriol, each at very low doses, with a
      placebo cream. Estradiol cream is available on prescription but we want to see how effective
      it is at one tenth the commonly prescribed dose. Estriol cream is not commonly prescribed and
      is only available at compounding pharmacies. We want to see if either of these estrogens is
      effective at one tenth the usual dose. We also want to see if these creams are effective when
      massaged onto the outer part of the vagina, rather than the usual method of treatment, which
      is inserting them into the vagina.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will measure the effects of very low doses of estradiol or estriol cream applied
      to the vaginal introitus for the treatment of atrophic vaginitis, a common condition
      affecting up to 40% of postmenopausal women. We will conduct a randomized controlled trial
      with three arms-estradiol, estriol and placebo. The intervention will last for 12 weeks. The
      outcomes we will be most interested in are the efficacy of the treatments for symptoms of
      atrophic vaginitis compared to placebo and whether there is any measurable systemic
      absorption from the locally applied estrogen creams. These outcomes will be measured,
      primarily, by the use of patient questionnaires and secondarily, clinical examination scores.
      Safety will be evaluated with serum estrogen concentrations. All measures will be collected
      at baseline and at the termination of the study. Hormone concentrations will be collected,
      additionally, at week 2. This trial will answer important questions regarding the impact of
      very low doses of locally applied estrogens and symptoms of atrophic vaginitis. It will
      provide information on effect size and validity of outcome measures. It will also give
      information about whether low doses of estrogen creams, locally applied to the vaginal
      introitus, result in systemic absorption
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Vulvovaginal Atrophy Questionnaire (VVAQ) Scores From Baseline to Week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The VVAQ consists of three questions asking the participant to rate the severity and how bothersome each of the symptoms of atrophic vaginitis are (dryness, itching, and burning). It is graded 0 through 10. A higher number indicates less severe and less bothersomeness of the symptom, that is, 0= very severe or bothersome, 10= least severe or bothersome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Estrone (E1) Levels Between Baseline, 2 Weeks, and 12 Weeks</measure>
    <time_frame>baseline, 2 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Estradiol (E2) Levels Between Baseline, 2 Weeks, and 12 Weeks</measure>
    <time_frame>baseline, 2 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Atrophic Vaginitis</condition>
  <arm_group>
    <arm_group_label>Estriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vanicream Lite</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol</intervention_name>
    <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.</description>
    <arm_group_label>Estriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol valerate</intervention_name>
    <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
    <arm_group_label>Estradiol</arm_group_label>
    <other_name>Delestrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vanicream Lite</intervention_name>
    <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
    <arm_group_label>Vanicream Lite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (no menses for the previous 12 months)

          -  Dryness, itching or burning in and around the vagina

          -  Discontinued hormone replacement therapy (either local or systemic) at least 3 months

        Exclusion Criteria:

          -  Known, suspected, or history of cancer of the breast.

          -  Known, or suspected estrogen dependent neoplasia (ovarian, endometrial).

          -  Known hypersensitivity to any component of the medications or base creams.

          -  Active deep vein thrombosis, pulmonary embolism, or history of these conditions.

          -  Active or recent (within the past year) arterial thromboembolic disease (stroke,
             myocardial infarct).

          -  Liver dysfunction or disease with elevation of aspartate aminotransferase (AST)&gt;1.5x
             upper level of normal (ULN); Normal for females is 8-43 U/L.

          -  Undiagnosed abnormal genital bleeding.

          -  Known chronic lichen sclerosis.

          -  Known, untreated vaginal infection.

          -  Not had a normal screening mammogram within the last 15 months.

          -  Hysterectomy without oophorectomy unless 60 years or older.

          -  Women taking aromatase inhibitors or tamoxifen.

          -  Hgb &lt;12.0 or &gt;15.5 g/dL

          -  Urinalysis showing a urinary tract infection (UTI).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maire B Mac Bride, MB BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2008</study_first_submitted>
  <study_first_submitted_qc>December 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2009</study_first_posted>
  <results_first_submitted>February 12, 2014</results_first_submitted>
  <results_first_submitted_qc>February 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2014</results_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Maire Mac Bride</investigator_full_name>
    <investigator_title>M.B., B. Ch., Assistant Professor of Medicine, College of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Atrophic Vaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Estriol</title>
          <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
        <group group_id="P2">
          <title>Estradiol</title>
          <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Estriol</title>
          <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
        <group group_id="B2">
          <title>Estradiol</title>
          <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Vulvovaginal Atrophy Questionnaire (VVAQ) Scores From Baseline to Week 12</title>
        <description>The VVAQ consists of three questions asking the participant to rate the severity and how bothersome each of the symptoms of atrophic vaginitis are (dryness, itching, and burning). It is graded 0 through 10. A higher number indicates less severe and less bothersomeness of the symptom, that is, 0= very severe or bothersome, 10= least severe or bothersome.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Estriol</title>
            <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vulvovaginal Atrophy Questionnaire (VVAQ) Scores From Baseline to Week 12</title>
          <description>The VVAQ consists of three questions asking the participant to rate the severity and how bothersome each of the symptoms of atrophic vaginitis are (dryness, itching, and burning). It is graded 0 through 10. A higher number indicates less severe and less bothersomeness of the symptom, that is, 0= very severe or bothersome, 10= least severe or bothersome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dryness Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.3"/>
                    <measurement group_id="O2" value="2.0" spread="3.3"/>
                    <measurement group_id="O3" value="2.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness Bothersomeness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.8"/>
                    <measurement group_id="O2" value="2.1" spread="2.7"/>
                    <measurement group_id="O3" value="3.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.6"/>
                    <measurement group_id="O2" value="2.6" spread="2.9"/>
                    <measurement group_id="O3" value="1.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching Bothersomeness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.6"/>
                    <measurement group_id="O2" value="2.6" spread="3.0"/>
                    <measurement group_id="O3" value="1.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.6"/>
                    <measurement group_id="O2" value="1.5" spread="2.5"/>
                    <measurement group_id="O3" value="1.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning Bothersomeness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.7"/>
                    <measurement group_id="O2" value="1.5" spread="2.6"/>
                    <measurement group_id="O3" value="1.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dryness severity: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dryness bothersomeness: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itching severity: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itching bothersomeness: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Burning severity: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Burning bothersomeness: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Estrone (E1) Levels Between Baseline, 2 Weeks, and 12 Weeks</title>
        <time_frame>baseline, 2 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Estriol</title>
            <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Estrone (E1) Levels Between Baseline, 2 Weeks, and 12 Weeks</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline vs. Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="4.6"/>
                    <measurement group_id="O2" value="-1.6" spread="3.8"/>
                    <measurement group_id="O3" value="0.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="4.4"/>
                    <measurement group_id="O2" value="1.2" spread="5.0"/>
                    <measurement group_id="O3" value="1.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 vs. Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.6"/>
                    <measurement group_id="O2" value="1.5" spread="3.4"/>
                    <measurement group_id="O3" value="0.6" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline vs. week 2: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline vs. week 12: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2 vs. week 12: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Estradiol (E2) Levels Between Baseline, 2 Weeks, and 12 Weeks</title>
        <time_frame>baseline, 2 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Estriol</title>
            <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Estradiol (E2) Levels Between Baseline, 2 Weeks, and 12 Weeks</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline vs. Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.1"/>
                    <measurement group_id="O2" value="-1.7" spread="3.3"/>
                    <measurement group_id="O3" value="0.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="3.0"/>
                    <measurement group_id="O2" value="0.6" spread="1.7"/>
                    <measurement group_id="O3" value="0.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 vs. Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.8"/>
                    <measurement group_id="O2" value="1.9" spread="3.6"/>
                    <measurement group_id="O3" value="-0.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline vs. week 2: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline vs. week 12: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2 vs. week 12: P-value for the global F-test testing for all treatment arm effects equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study coordinator contacted the participants every 2 weeks and asked the questions on the Adverse Events Stopping Rules. The participant was contacted again at 4 weeks after completion of the study to determine if further side effects had occurred.</time_frame>
      <desc>Subjects also completed the Symptoms Inventory Questionnaire at baseline, 2, 4, 8, and 12 weeks. If subjects experienced a serious adverse event they were to be withdrawn from the study. These events included elevated blood pressure, a breakdown of vulvar or vaginal skin, or possible allergy to the medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Estriol</title>
          <description>Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
        <group group_id="E2">
          <title>Estradiol</title>
          <description>Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTEP 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Spotting</sub_title>
                <description>The subject on placebo arm experienced at week 4, the subject on estriol arm experienced 4 weeks after completion of study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Red Bumpy Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maire Brid MacBride MB BCh</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-538-2271</phone>
      <email>MacBride.Maire@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

